What Apobiologix does

Apobiologix is a specialty pharmaceutical division of Apotex Inc., headquartered in Toronto, Canada, focused on developing and commercializing biosimilar medicines for the Canadian market. Its portfolio comprises three marketed oncology biosimilars — Bambevi and Grastofil (filgrastim biosimilars) and Lapelga (pegfilgrastim biosimilar) — used for prevention and treatment of chemotherapy-induced neutropenia. Apobiologix develops these products in partnership with Apotex's broader manufacturing infrastructure, leveraging Health Canada-approved biosimilar regulatory pathways and a commercial approach centered on HCP engagement, formulary listing, and patient support.

The company monetizes through product sales to Canadian hospital and institutional pharmacies, community pharmacies, and ultimately reimbursed by provincial/territorial public drug plans and private insurers. Its go-to-market combines a traditional field-sales model targeting oncologists and oncology pharmacists with a multi-channel stakeholder engagement program — the Apobiologix Partnership Program (APP) — that includes educational fellowships (ASH/ASCO sponsorships), the ABC Program, HOPE Awards, and the Quebec Oncology Pharmacist Partnership Program. Direct patient access is facilitated through the ANSWERS patient support program (with ANSWERS Select for copay support), which has supported more than 30,000 patients since 2016 and provides injection training for Lapelga's pre-filled syringe and autoinjector formats.

Apobiologix positions itself as a pioneer and leader in oncology biosimilars in Canada, building on Apotex's 40+ year domestic pharmaceutical heritage. It maintains a stated pipeline of additional biosimilars targeting new therapeutic areas beyond oncology supportive care. Operationally the unit is supported by a leadership team spanning medical affairs, market access, sales, marketing, and operations, with explicit responsibility for biosimilar commercialization strategy and pan-Canadian reimbursement engagement, including participation in the Biosimilars Market Access Committee.

Name

Apobiologix

Legal name

Apotex Inc.

Website

https://apobiologix.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Apobiologix is a Toronto-based specialty pharmaceutical division of Apotex Inc. that develops and commercializes biosimilar oncology supportive-care medicines (filgrastim and pegfilgrastim) for Canadian patients, healthcare providers, and public drug plans.

Ownership category

akta.pro rank

Product category

Oncology Biosimilars

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Monoclonal Antibody (mAb) Biosimilars (HLAIAFAA)

akta.pro secondary industry

Biologics & Biosimilars Distributors (HLAIAJAH)

Keywords

• Oncology biosimilars
• Biosimilar pharmaceuticals
• Patient support programs
• Biologic medicines
• Pharmaceutical commercialization

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Biosimilar Product Sales: Apobiologix generates revenue through the sale of marketed biosimilar products including Bambevi (filgrastim biosimilar), Grastofil (filgrastim biosimilar), and Lapelga (pegfilgrastim biosimilar). These products are sold to healthcare providers, hospitals, and through pharmacies in Canada. Revenue comes from product sales to the Canadian healthcare system including public drug plans and private insurers.
2. Pipeline Product Development: The company continues investing in a pipeline of additional biosimilars in oncology and expanding to new therapeutic areas, suggesting future revenue streams from new product launches.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Apobiologix is a division of Apotex Inc. that develops, manufactures, and commercializes biosimilar versions of oncology biologic medicines in Canada. Its marketed portfolio consists of three products — Bambevi and Grastofil (filgrastim biosimilars) and Lapelga (pegfilgrastim biosimilar) — used for the prevention and treatment of chemotherapy-induced neutropenia. The company complements the products with patient and healthcare-provider support programs (ANSWERS and the Apobiologix Partnership Program).

Product overview

Apobiologix is a division of Apotex Inc. focused on the commercialization of biosimilars in Canada. The company operates as a pioneer and leader in oncology biosimilars, offering a portfolio of three marketed products: Bambevi, Grastofil (filgrastim), and Lapelga (pegfilgrastim). These biosimilar products provide affordable supportive care therapies for cancer patients undergoing chemotherapy, addressing neutropenia management. Apobiologix also maintains a pipeline of additional biosimilars and has a patient support program called ANSWERS, an HCP support program, and the Apobiologix Partnership Program (APP) for stakeholder engagement.

Differentiator

Problem solved

Functional benefit

Brands

• ANSWERS: Comprehensive patient support program dedicated to helping Canadian patients prescribed an Apobiologix product gain access to their medication.
• ANSWERS Select
• APP (Apobiologix Partnership Program)
• HOPE Awards
• ABC Program

Products and services

• Bambevi (biosimilar) Bambevi is an Apobiologix-marketed biosimilar product intended for supportive care in oncology patients; product monograph and patient medication information are published.
• Grastofil (filgrastim biosimilar) Grastofil is a filgrastim biosimilar used for the prevention and treatment of neutropenia in cancer patients undergoing chemotherapy, administered via pre-filled syringe.
• Lapelga (pegfilgrastim biosimilar) Lapelga is a pegfilgrastim biosimilar for reducing the incidence of febrile neutropenia in patients treated with chemotherapy, available as a pre-filled syringe and a pre-filled autoinjector.

Quantifiable outcome

• 30,000+ patients supported since 2016 through ANSWERS patient support program
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Intas Pharmaceuticals / Accord HealthcareminorStrategic or Co-development Partner · 1 August 2025In August 2025, Intas Pharmaceuticals partnered with Accord Healthcare to acquire the Udenyca product line from Coherus Biosciences, forming one of the world's largest pegfilgrastim suppliers. This is noted as market context for the filgrastim biosimilars market in which Apobiologix operates with its Lapelga product.
• Healthcare Provider PartnerscoreStrategic or Co-development PartnerApobiologix works in cooperation with healthcare provider partners to enhance patient access, optimize patient care, and ensure sustainability of the Canadian healthcare system. This includes pharmacists, physicians, and oncology specialists who prescribe and manage biosimilar therapies.
• IMD HealthminorStrategic or Co-development PartnerApobiologix supports the IMD Health Education Program as part of the APP's Educational Patient Resources pillar. IMD Health provides patient education resources to support the disease journey for patients.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Amgen: Amgen is both the originator of reference biologics in the G-CSF space (Neupogen, Neulasta) and a developer of biosimilars. Apobiologix competes against Amgen's originator franchise while operating in the biosimilar space, and Amgen's leadership team (SVP Mike Woolcock) previously held roles at Amgen.
• Viatris: Viatris (Mylan/Upjohn combination) markets biosimilars including a portfolio that competes in oncology supportive care. They are a broad incumbent with global commercial reach including Canada, and a comparable generics-plus-biosimilars commercial model.
• Sandoz: Sandoz is the global market leader in biosimilars, with a broad oncology biosimilar portfolio including filgrastim/pegfilgrastim (Zarxio, Ziextenzo) and many other molecules. It competes directly with Apobiologix's Grastofil and Lapelga in the same therapeutic class, but operates at vastly greater geographic scale.
• Pfizer: Pfizer (post-Hospira integration) markets multiple biosimilars including Nivestym (filgrastim biosimilar) directly competitive with Apobiologix's Grastofil. As a broad incumbent pharmaceutical major, Pfizer has global scale advantages in manufacturing and commercialization.
• Teva Pharmaceutical Industries: Teva markets biosimilars including oncology supportive care products and has a presence in Canada. As a broad pharmaceutical incumbent with both generics and biosimilars, Teva overlaps with Apobiologix's commercial model in the Canadian market.

Direct peers

• Coherus BioSciences: Coherus is a focused biosimilar developer and commercializer with Udenyca (pegfilgrastim biosimilar) as a flagship product directly competitive with Lapelga. Coherus is a closely comparable pure-play biosimilar commercialization company, though larger in geographic scope.
• Samsung Bioepis: Samsung Bioepis is a leading dedicated biosimilar developer with multiple approved products across oncology, immunology, and ophthalmology. They compete with Apobiologix in the G-CSF class and represent a focused biosimilar pure-play comparable in business model.
• Celltrion: Celltrion is a South Korean biosimilar-focused manufacturer with a portfolio including oncology supportive care biosimilars. As a pure-play biosimilar developer-commercializer, Celltrion is highly comparable in business model to Apobiologix, though at a much larger global scale.
• Accord Healthcare (Intas Pharmaceuticals): Following the August 2025 acquisition of Coherus' Udenyca pegfilgrastim franchise, Accord/Intas became one of the world's largest pegfilgrastim suppliers. They directly compete with Apobiologix's Lapelga in the G-CSF biosimilar market globally and likely in Canada via distribution.

Emerging players

• Biocon: Biocon Biologics is a global biosimilar developer with oncology and immunology biosimilars marketed in developed markets. As a focused biosimilar player with global ambitions, Biocon is comparable in business model to Apobiologix but operates at a larger international scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/apobiligix

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apobiologix